Overview

Study to Demonstrate the Non-inferiority of Olmesartan Medoxomil Versus Candesartan Cilexetil in Reducing Blood B-type (or Brain) Natriuretic Peptide Levels at Week 24

Status:
Terminated
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
This study will compare olmesartan medoxomil to candesartan cilexetil in reducing BNP, a prognostic biomarker of heart failure, at week 24
Phase:
Phase 3
Details
Lead Sponsor:
Daiichi Sankyo Europe, GmbH
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Treatments:
Candesartan
Candesartan cilexetil
Olmesartan
Olmesartan Medoxomil